A team led by Peter Schultz, Scripps Family Chair Professor and member of the Skaggs Institute for Chemical Biology at The Scripps Research Institute, has been awarded a $4.3 million grant from the California Institute for Regenerative Medicine (CIRM) to research stem-cell-based therapies to treat multiple sclerosis.
Because stem cells can change or differentiate into many different cell types (such as nerve cells, muscle cells, and skin cells), they hold the life-changing medical potential to provide a source of cells to replace those permanently lost by a patient.
The Scripps Research project focuses on restoring the myelin sheath—a protective covering that
International Stem Cell Corporation, announces that it has launched fifteen new human cell culture products into the commercial research markets over the last twelve months through its wholly-owned subsidiary, Lifeline Cell Technology, (Walkersville, MD), leading to a 12-month average month-to-month revenue growth of 50%. ISCO, the parent company, is the first company to create human “parthenogenetic” stem cells from unfertilized eggs. Parthenogenetic stem cells not only solve ethical problems, but also promise to minimize immune-rejection by providing cells that can be immune-matched to large segments of the population.
These products represent milestone
Image via CrunchBase
Two critical programs funded by the California Institute for Regenerative Medicine, the state stem cell agency, got a $11 million increase today when the agency’s 29-member Governing Board voted to approve funding for two additional grants in the Training II program and five additional grants in the Bridges program.
The grants voted in today had been recommended by the Scientific and Medical Research Funding Working Group for funding if funds permit. In January 2009, when the Board considered those applications, they voted to fund only the top tier due to uncertainty in the bond market. With improvements in
UC Davis Health System researchers who are working to speed therapies to patients suffering from critical limb ischemia, osteoporosis and Huntington’s disease received approval today for three separate research grants from the state’s stem cell agency totaling more than $53 million. Each of the research studies that can now begin at UC Davis are specifically designed to lead to U.S. Food and Drug Administration approval of human clinical trials using stem cells and regenerative therapies.
At today’s meeting of the California Institute for Regenerative Medicine (CIRM) in San Francisco, the agency’s 29-member governing board approved five other grant
Image by Getty Images via Daylife
Sheng Ding, the leader of a group of researchers at the Scripps Research Institute of the La Jolla University in California, spoke about using chemistry-related techniques to obtain pluripotent stem cells from a miniscule section of skin at Milan University in a conference on stem cells.
Experts were able to cause some skin cells in mice to regress to their embryonic state by injecting four proteins into an adult mouse without performing any sort of DNA manipulation. A technique that, according to their idea, could be safer than techniques based on genetic manipulation. The